Navigation Links
For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations

BURLINGTON, Mass., Sept. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of multiple myeloma, more surveyed European hematologist-oncologists consider the combination of immunomodulatory agents and proteasome inhibitors promising with respect to efficacy than is the case for any other drug regimen combinations. In light of these findings, the emerging regimen of Onyx Pharmaceuticals' carfilzomib in combination with Celgene's Revlimid has the potential to be the most efficacious strategy for multiple myeloma treatment.

The new European Physician & Payer Forum report entitled European Physician and Payer Perspectives in Myeloma: How Will Emerging Therapies Compete With Well-Entrenched Brands? explores the future market dynamics for this indication in light of several highly-promising emerging agents in multiple myeloma. Although other agents are frequently used to treat the indication, Revlimid, Janssen-Cilag's Velcade and Celgene's Thalidomide together captured more than 80 percent of the multiple myeloma market in 2008 in France, Germany, Italy, Spain and the United Kingdom (EU5).

"Most surveyed European hematologist-oncologists indicate that Velcade is commonly used in the first-line setting while Revlimid-based regimens are more commonly used in the second- and third-line," said Decision Resources Analyst Andrew Merron, Ph.D. "Emerging agents such as carfilzomib are expected to enter the relapsed/refractory settings and will be used either in combination with Revlimid, Velcade and Thalidomide or they will compete directly with these agents. Other key agents in late stage development include Celgene's pomalidomide, AEterna Zentaris/Keryx Biopharmaceuticals' perifosine, Merck's Zolinza and Novartis's panobinostat."  

According to the report, most hematologist-oncologists in the EU5 consider patients who are relapsed from or refractory to Velcade to be candidates for carfilzomib in combination with Revlimid.

The report also finds that surveyed payers in both Germany and Spain are questioning how long automatic reimbursement of drugs that have been approved by the European Medicines Agency can last. While several countries have imposed mandatory price cuts on pharmaceuticals, or will do so imminently, the uncertain future of automatic reimbursement policies may have an even more significant market impact than mandatory price cuts.

"Interviewed payers have warned that the days of automatic reimbursement of high-cost targeted cancer therapies may be numbered, particularly when multiple new drugs become available for an indication like myeloma," Dr. Merron said.

The report is based on a survey of 251 hematologist-oncologists from Germany (52), France (50), Italy (49), Spain (50) and the United Kingdom (50) and interviews with 15 European payers from Germany (3), France (3), Italy (3), Spain (3) and the United Kingdom (3).

About Decision ResourcesDecision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
2. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
3. Fertility Drugs Contribute Heavily to Multiple Births
4. Clinical Benefits of Electronic Brachytherapy From Xoft Substantiated for the Treatment of Multiple Cancers
5. Volcano Announces Plans to Introduce Multiple New Products at EuroPCR 2010
6. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
7. Fortis Hospitals Puts 27 Year Old Nigerian Back on her Feet After Multiple Joint Replacement Surgery
8. SRI International Researchers Present Promising New Therapeutic for the Treatment of Multiple Myeloma
9. Multiple Chemical Sensitivities Are Real
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
Post Your Comments:
(Date:11/26/2015)... UTRECHT, the Netherlands , November 26, 2015 /PRNewswire/ ...   A new combination approach blends immunotherapy ... --> A new combination approach blends immunotherapy with ... A new combination approach blends immunotherapy with ... the Netherlands has found that immunotherapy ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Japanese therapeutic drug monitoring market, including emerging ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... "Advanced Wound Care Market by Type (Dressings, Therapy Devices, ... (In-Patient Facility, Out-Patient Facility), and Geography - Global Forecast ... --> --> The purpose ... and forecast of the global advanced wound care market. ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... through sharing, the 2016 Building Better Radiology Marketing Programs meeting will ... on Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in America", ... delves into an array of issues that are presently affecting Americans. Dedicated to providing ... this show is changing the subjects consumers focus on, one episode at a time. ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... innovative online platform for mental health and wellness consultation, has collaborated with a ... will bridge the knowledge gap experienced by parents and bring advice from parenting ...
(Date:11/27/2015)... Chicago, IL (PRWEB) , ... November 27, 2015 ... ... some of the largest, most successful and prominent nonprofit healthcare organizations in the ... and governance involvement with various organizations, and helped advance the healthcare industry as ...
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley from Vintage ... style concert posters. This is one of Joplin's most famous and beautiful concert posters. ... University of Michigan in Ann Arbor. The According to Hawley, "It is hard to ...
Breaking Medicine News(10 mins):